These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32361904)

  • 21. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.
    Tomlinson B; Hu M; Lee VW; Lui SS; Chu TT; Poon EW; Ko GT; Baum L; Tam LS; Li EK
    Clin Pharmacol Ther; 2010 May; 87(5):558-62. PubMed ID: 20130569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
    Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
    Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers.
    Zhao G; Liu M; Wu X; Li G; Qiu F; Gu J; Zhao L
    Pharmacogenomics; 2017 Jan; 18(1):65-75. PubMed ID: 27967318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Food Effect on Rosuvastatin Disposition and Low-Density Lipoprotein Cholesterol.
    McLean CC; Teft WA; Morse BL; Gryn SE; Hegele RA; Kim RB
    Clin Pharmacol Ther; 2018 Sep; 104(3):525-533. PubMed ID: 29218707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
    Lee N; Maeda K; Fukizawa S; Ieiri I; Tomaru A; Akao H; Takeda K; Iwadare M; Niwa O; Masauji T; Yamane N; Kajinami K; Kusuhara H; Sugiyama Y
    Drug Metab Pharmacokinet; 2019 Dec; 34(6):387-395. PubMed ID: 31594719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.
    Wagner JB; Abdel-Rahman S; Gaedigk A; Gaedigk R; Raghuveer G; Staggs VS; Van Haandel L; Leeder JS
    Clin Transl Sci; 2020 May; 13(3):628-637. PubMed ID: 31981411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.
    Lehtisalo M; Taskinen S; Tarkiainen EK; Neuvonen M; Viinamäki J; Paile-Hyvärinen M; Lilius TO; Tapaninen T; Backman JT; Tornio A; Niemi M
    Br J Clin Pharmacol; 2023 Jan; 89(1):242-252. PubMed ID: 35942816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The frequency of rs2231142 in
    AlAzzeh O; Roman YM
    Pharmacogenomics; 2023 Feb; 24(3):173-182. PubMed ID: 36661065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
    Lee E; Ryan S; Birmingham B; Zalikowski J; March R; Ambrose H; Moore R; Lee C; Chen Y; Schneck D
    Clin Pharmacol Ther; 2005 Oct; 78(4):330-41. PubMed ID: 16198652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The frequency of rs2231142 in
    Alrajeh K; Roman YM
    Pharmacogenomics; 2023 Jan; 24(1):15-26. PubMed ID: 36651271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
    Hu M; Tomlinson B
    Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study.
    Liu JE; Liu XY; Chen S; Zhang Y; Cai LY; Yang M; Lai WH; Ren B; Zhong SL
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1409-1416. PubMed ID: 28812116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
    Cooper-DeHoff RM; Niemi M; Ramsey LB; Luzum JA; Tarkiainen EK; Straka RJ; Gong L; Tuteja S; Wilke RA; Wadelius M; Larson EA; Roden DM; Klein TE; Yee SW; Krauss RM; Turner RM; Palaniappan L; Gaedigk A; Giacomini KM; Caudle KE; Voora D
    Clin Pharmacol Ther; 2022 May; 111(5):1007-1021. PubMed ID: 35152405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
    Ferrari M; Guasti L; Maresca A; Mirabile M; Contini S; Grandi AM; Marino F; Cosentino M
    Eur J Clin Pharmacol; 2014 May; 70(5):539-47. PubMed ID: 24595600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study.
    Mirošević Skvrce N; Macolić Šarinić V; Šimić I; Ganoci L; Muačević Katanec D; Božina N
    Pharmacogenomics; 2015 Jul; 16(8):803-15. PubMed ID: 26086347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight.
    Wegler C; Prieto Garcia L; Klinting S; Robertsen I; Wiśniewski JR; Hjelmesaeth J; Åsberg A; Jansson-Löfmark R; Andersson TB; Artursson P
    Clin Pharmacol Ther; 2021 Mar; 109(3):762-771. PubMed ID: 32970864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
    Keskitalo JE; Zolk O; Fromm MF; Kurkinen KJ; Neuvonen PJ; Niemi M
    Clin Pharmacol Ther; 2009 Aug; 86(2):197-203. PubMed ID: 19474787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.